The global autoimmune diagnostics market size was worth USD 14.54 billion in 2021 and is forecasted to be worth USD 17.35 billion by the end of 2026. This market registers a CAGR of 3.6% during the forecast period.
Autoimmune disease is a disorder where the patient’s immune system attacks its body tissues, leading to body organs' damage. Nearly 80 types of autoimmune diseases are known so far.
MARKET DRIVERS:
The high incidences of autoimmune diseases and growing awareness about autoimmune diseases further contribute to the growth of the global autoimmune diagnostics market.
The global autoimmune diagnostics market is forecasted to have tremendous growth during the forecast period. It is receiving a significant boost from a rise in the prevalence of autoimmune disorders like people with type 1 diabetes in newborn babies with copulation of demand for rapid diagnostics.
Additionally, a rise in R & D on autoimmune diseases is predicted to favor the market's growth rate. Across the globe, many research and diagnostics industries are undertaking new initiatives with a complication with government organizations by owning a rise in the prevalence of autoimmune disorders. They will have a consequence on healthcare expenditure, as per the National Institutes of Health (NIH) data published that these disorders are in the top ranking, which leads to an increment in mortality rates among women. The factors mentioned above are the primary and significant drivers of the autoimmune diagnostics market.
MARKET RESTRAINTS:
Some of the restraints factors, such as the high frequency of false-positive results and having an extended turnaround time for diagnostic test results, limit the market growth to a small extent. In addition, high expenditures, less awareness regarding various diseases, and diagnostic measures are other significant restraints. Moreover, fewer income companies and the rise of economy countries to address some issues for autoimmune diseases diagnostics market.
Impact of COVID-19 on the global autoimmune diagnostics market:
The novel coronavirus caused by the SARS-CoV-2reagent and has disrupted every sector worldwide. The medical industry has observed severe ups and downs during the pandemic crisis. In general, women with frequent autoimmune rheumatic diseases have a similar risk compared to men over the pandemic time. The pandemic has imposed some challenges for patients with immune involved with inflammatory autoimmune systemic disorders. One of the government's top issues from COVID-19 is the unbearable necessity of examining and testing many people for virus infection. Some infected patients may develop autoimmune situations like SLE, multiple sclerosis, and some autoinflammatory conditions in children. The autoimmune diagnostics market faces some challenges with a heavy burden in supplying efficient test kits and accelerating the medical industry's attention. There has been an expanding case of rheumatoid arthritis (RA) is registered post different viral outbreaks. As of May 13, 2020, 872 rheumatic patient cases were reported infected with coronavirus as per the COVID 19 Global Rheumatology Alliance.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Test Type, Disease Type & Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly, and GlaxoSmithKline Plc. |
This research report on the global autoimmune diagnostics market has been segmented and sub-segmented based on the test type, disease type, and region.
Autoimmune Diagnostics Market - By Test Type:
The autoantibody tests segment is predicted to dominate the global market during the forecast period based on the test type. An autoantibody is the largest among all the elements of the autoimmune diagnostics market.
Autoimmune Diagnostics Market - By Disease Type:
Based on the disease type, the localized autoimmune disease diagnostics segment was the market leader in 2020 and is predicted to witness healthy growth during the forecast period. The segment is majorly driven by the heavy procedural volumes and relevantly high compared to systemic autoimmune disease diagnostics. As per the American Autoimmune Related Diseases Association, approximately 50 million people are suffering from related autoimmune disorders.
The systematic autoimmune disease diagnostics market is expected to grow at the fastest CAGR during the forecast period. Due to the burgeoning prevalence of rheumatoid arthritis, the rheumatoid arthritis segment, surging consciousness of the disease, and government support, aid in market development. For example, Amgen exhibited a safety trial for diagnostics in treating Systematic Lupus Erythematous.
Autoimmune Diagnostics Market - By End User:
Based on the end-user, the hospital end-user segment is projected to play a leading role in the global autoimmune diagnostics market growth. Hospitals use advanced technologies to organize multiple tests at the same time with robust and appropriate results. The surging autoimmune disease consultations
The research centers and diagnostic labs worldwide are likely to encourage measures in coordinating with the government sectors due to growing incidences of autoimmune disorders and expansion of investments in the healthcare field. These factors represent the segment's growth worldwide. In addition, many of the research and diagnostic centers commit to organizing public awareness activities in educating singles regarding autoimmune diseases and possible treatment options and diagnoses. The mentioned factors influence the segment positively.
Autoimmune Diagnostics Market - By Region:
Geographically, the North American region is estimated to rule the global autoimmune diagnostics market during the forecast period with the highest share, followed by Europe, Asia Pacific. The Asia-pacific market is expected to account for the highest growth during the forecast period.
As anticipated, the North American region contributed to the highest revenue share above 39.2% in 2019. This North American region is owning factors such as the presence of favorable initiatives and regulations by AARDA. Moreover, the North American area is also having a high prevalence of diseases.
During the forecast period, the Asia-Pacific region has a lucrative growth-share by owning many advantages such as improving healthcare infrastructure and the rapid growth of patients’ awareness levels. Moreover, the Asia-Pacific region is having a rise in an increment of revenue share. As a result, the expected revenue share of the autoimmune diagnostics market in the Asia-Pacific region has a CAGR of over 22.0%, from 19.5% in 2015 to 2025.
The European region is also accounting highest share due to the presence of UK country during the forecast period. Furthermore, the European region has advantageous factors such as increment of economic burden with copulation with increased research and developed activities further influencing the European region's growth. Additionally, the increment of demand for better and accurate diagnosis for systematic localized diseases positively impacts the autoimmune diagnostic market.
KEY MARKET PLAYERS:
Notable participants leading the global autoimmune diagnostics market profiled in the report are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly and GlaxoSmithKline Plc.
RECENT MARKET HAPPENINGS:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Test Type
5.1.1 Autoantibody Tests
5.1.2 Antinuclear Antibody Tests
5.1.3 Complete Blood Count (CBC)
5.1.4 C - reactive protein (CRP)
5.1.5 Comprehensive Metabolic panel
5.1.6 Urinalysis
5.1.7 Erythrocyte Sedimentation Rate (ESR)
5.1.8 Others
5.2 By Disease Type
5.2.1 Localized auto immune disease diagnostics
5.2.1.1 Graves' Disease
5.2.1.2 Hashimoto's Thyroiditis
5.2.1.3 Multiple Sclerosis
5.2.1.4 Type 1 diabetes
5.2.1.5 Psoriasis
5.2.1.6 Others
5.2.2 Systemic auto immune disease diagnostics
5.2.2.1 Rheumatoid Arthritis (RA)
5.2.2.2 Ankylosing Spondylitis
5.2.2.3 Systemic Lupus Erythematosus (SLE)
5.3 By End Users
5.3.1 Hospitals
"5.3.2 Research centers
"
5.3.3 Diagnostic laboratories
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bio-Rad
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Siemens Healthcare
8.3 Abbott Laboratories
8.4 Crescendo Bioscience
8.5 Roche Diagnostics
8.6 SQI Diagnostics
8.7 AESKU Diagnostics
8.8 INOVA Diagnostics
8.9 BioMerieux SA
8.10 Beckman Coulter Inc.
8.11 Hemagen Diagnostics
8.12 Quest Diagnostics
8.13 Eli lilly
8.14 Glaxosmithkline Plc
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
